fluconazole has been researched along with mk-3118 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 7 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Angulo, D; Helou, S; Pappas, PG; Powderly, WG; Pullman, J; Spec, A; Thompson, GR; Tobin, EH; Vazquez, J; Wring, SA | 1 |
| Angulo, D; Azie, N; Borroto-Esoda, K; Sobel, JD | 1 |
| Angulo, DA; Azie, NE; Harriott, IA; Nyirjesy, P; Schwebke, JR; Sobel, JD | 1 |
| Díaz-García, J; Escribano, P; Guinea, J; Mesquida, A; Muñoz, P; Sánchez-Carrillo, C | 1 |
| Alcalá, L; Cuétara, MS; Díaz-García, J; Durán-Valle, MT; Escribano, P; García-Esteban, C; Gómez, A; Gómez-García De La Pedrosa, E; González-Romo, F; Guinea, J; Machado, M; Muñoz, P; Muñoz-Algarra, M; Pérez-Ayala, A; Quiles-Melero, I; Reigadas, E; Sánchez-Carrillo, C; Sánchez-García, A; Zurita, ND | 1 |
| Chahine, EB; Mantena, N; Noronha, A; Sucher, AJ; Thai, A; Tran, C | 1 |
| Merjanian, L; Phillips, NA; Rocktashel, M | 1 |
| Díaz-García, J; Escribano, P; Guinea, J; Machado, M; Mesquida, A; Muñoz, P; Sánchez-Carrillo, C | 1 |
1 review(s) available for fluconazole and mk-3118
| Article | Year |
|---|---|
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Topics: Antifungal Agents; Azoles; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Polyenes; Pregnancy; Triterpenes | 2023 |
2 trial(s) available for fluconazole and mk-3118
| Article | Year |
|---|---|
MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Candida; Candidiasis, Invasive; Echinocandins; Female; Fluconazole; Glycosides; Humans; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Triterpenes | 2019 |
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Glycosides; Humans; Triterpenes | 2022 |
5 other study(ies) available for fluconazole and mk-3118
| Article | Year |
|---|---|
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; Glycosides; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Pichia; Triterpenes | 2021 |
In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method.
Topics: Antifungal Agents; Blood Culture; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropicalis; Candidemia; Drug Resistance, Fungal; Echinocandins; Fluconazole; Glycosides; Humans; Microbial Sensitivity Tests; Triterpenes | 2022 |
Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris.
Topics: Antifungal Agents; Candida; Candida auris; Candida parapsilosis; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests | 2022 |
Ibrexafungerp: A new triterpenoid antifungal.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Child; Echinocandins; Female; Fluconazole; Humans; Pregnancy; Triterpenes | 2022 |
Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity.
Topics: Animals; Antifungal Agents; Blood Culture; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropicalis; COVID-19; Drug Resistance, Fungal; Fluconazole; Fungemia; Microbial Sensitivity Tests; Pandemics; Tertiary Care Centers | 2023 |